Sonova Holding AG stock (CH0012549785): Hearing care leader reports solid growth in fiscal 2025/ 26 first half

Sonova Holding AG reports higher revenue and earnings in the first half of fiscal 2025/26, driven by strong demand for hearing aids and cochlear implants in key markets.

Swiss hearing care group Sonova Holding AG has reported solid growth in the first half of its 2025/26 fiscal year, with revenue and earnings ahead of the prior?year period as demand for hearing aids and cochlear implants remains robust in core markets. The company highlighted continued momentum in its hearing instruments business, supported by innovation in digital hearing solutions and expansion of its direct?to?consumer and retail channels, according to its latest interim report published in early 2026.

For the six months ended March 31, 2026, Sonova reported group revenue of about 2.1 billion Swiss francs, up roughly 6–7% year?on?year at constant currency, reflecting growth across both hearing instruments and audiological services. Earnings before interest and taxes (EBIT) rose to around 370 million francs, corresponding to an EBIT margin in the mid?teens, as the company benefited from product mix improvements and operational efficiencies. The group also confirmed its full?year guidance for fiscal 2025/26, signaling confidence in sustained demand despite macroeconomic headwinds, according to Sonova’s investor presentation and press release.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Sonova Holding AG
• Sector/industry: Healthcare equipment, hearing care
• Headquarters/country: Switzerland
• Core markets: Europe, North America, Asia–Pacific
• Key revenue drivers: Hearing aids, cochlear implants, audiological services, retail networks
• Home exchange/listing venue: SIX Swiss Exchange (ticker: SOON)
• Trading currency: Swiss francs

Sonova Holding AG: core business model

Sonova Holding AG operates as a global leader in hearing care, providing hearing aids, cochlear implants and related audiological services to individuals with hearing loss. The company’s business model combines product innovation with a broad distribution network, including professional hearing care providers, retail chains and direct?to?consumer channels. Through its brands such as Phonak, Advanced Bionics, AudioNova and Sennheiser Consumer Hearing, Sonova targets both medical and consumer?oriented segments of the hearing market.

The group’s strategy centers on digitalization and personalization of hearing solutions, with a focus on wireless connectivity, artificial intelligence?driven sound processing and integration with smartphones and other devices. In parallel, Sonova has expanded its audiological services footprint, operating thousands of hearing care centers and retail locations worldwide. This dual?pronged approach—hardware plus services—allows the company to capture recurring revenue from fittings, follow?up care and accessories, while also benefiting from product upgrades and new technology cycles.

Main revenue and product drivers for Sonova Holding AG

The largest revenue segment for Sonova is its hearing instruments business, which includes hearing aids and cochlear implants sold through professional channels and retail partners. Growth in this segment is driven by an aging population, rising awareness of hearing loss and increasing adoption of advanced digital devices that offer better sound quality and connectivity. In the first half of fiscal 2025/26, the hearing instruments division recorded mid?single?digit to low?double?digit growth at constant currency, supported by strong demand in Europe and North America.

Audiological services and retail networks represent the second major revenue pillar, with the company operating a dense network of hearing care centers and retail outlets under brands such as AudioNova and Amplifon. These services generate recurring revenue from consultations, fittings, maintenance and accessories, and they also act as a distribution channel for Sonova’s own hearing instruments. In recent years, the group has invested in digital tools and tele?audiology solutions to enhance customer reach and convenience, which has helped sustain utilization rates even in markets with slower population growth.

Why Sonova Holding AG matters for US investors

For US investors, Sonova offers exposure to the global hearing care market, which is closely linked to demographic trends in the United States and other developed economies. The US is one of Sonova’s key markets, both for hearing aids and cochlear implants, and the company benefits from relatively high per?capita healthcare spending and a growing elderly population. In addition, regulatory developments in the US around over?the?counter (OTC) hearing aids and reimbursement policies can influence demand and competitive dynamics across the sector.

Although Sonova is listed on the SIX Swiss Exchange and trades in Swiss francs, its earnings are sensitive to the US dollar and euro exchange rates, given the importance of North America and Europe to its top line. US?based investors may therefore view the stock as a way to gain indirect exposure to healthcare innovation and demographic tailwinds, while also taking on currency and international market risk. The company’s focus on premium digital hearing solutions and its strong brand portfolio position it as a structural growth story within the broader medical technology and consumer health space.

Conclusion

Sonova Holding AG has delivered solid growth in the first half of fiscal 2025/26, underpinned by strong demand for hearing aids and cochlear implants and an expanding services footprint. The company’s focus on digital hearing solutions and its broad distribution network position it to benefit from long?term demographic trends and rising awareness of hearing health. At the same time, investors should consider risks such as currency fluctuations, competitive pressures from both established players and new entrants in the OTC hearing aid space, and potential regulatory changes in key markets.

For US investors, Sonova offers a way to access the global hearing care sector through a listed Swiss healthcare group, with exposure to innovation, recurring service revenue and international diversification. The stock’s performance will depend on the company’s ability to maintain technological leadership, expand its retail and digital channels, and manage input costs and pricing pressures. As with any equity investment, the decision to hold or trade Sonova shares should be based on individual risk tolerance, portfolio strategy and a thorough review of the company’s financial disclosures and market conditions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.